Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients A Randomized Clinical Trial

Fecha de publicación: 27/11/2018

Autores de IIS La Fe

Esther Villarreal Tello

Autor
Jesús Ruiz Ramos

Autor

Participantes ajenos a IIS La Fe

Wittekamp, BH
Plantinga, NL
Cooper, B
Lopez-Contreras, J
Coll, P
Mancebo, J
Wise, MP
Morgan, MPG
Depuydt, P
Boelens, J
Dugernier, T
Verbelen, V
Jorens, PG
Verbrugghe, W
Malhotra-Kumar, S
Damas, P
Meex, C
Leleu, K
van den Abeele, AM
de Matos, AFGP
Mendez, SF
Gomez, AV
Tomic, V
Sifrer, F
Aragao, I
Santos, C
Sperning, RHM
Coppadoro, P
Nardi, G
Brun-Buisson, C
Bonten, MJM

Grupos

Infecciones Respiratorias

Investigador Principal

Raúl Méndez Ocaña
Medicina Intensiva

Leader

Álvaro Castellanos Ortega

Abstract

IMPORTANCE The effects of chlorhexidine (CHX) mouthwash, selective oropharyngeal decontamination (SOD), and selective digestive tract decontamination (SDD) on patient outcomes in ICUs with moderate to high levels of antibiotic resistance are unknown. OBJECTIVE To determine associations between CHX 2%, SOD, and SDD and the occurrence of ICU-acquired bloodstream infections with multidrug-resistant gram-negative bacteria (MDRGNB) and 28-day mortality in ICUs with moderate to high levels of antibiotic resistance. DESIGN, SETTING, ANDPARTICIPANTS RandomizedtrialconductedfromDecember1,2013, toMay 31, 2017, in 13 European ICUs where at least 5% of bloodstream infections are caused by extendedspectrum beta-lactamase-producingEnterobacteriaceae. Patientswithanticipatedmechanicalventilation of more than 24 hourswere eligible. The final date of follow-upwas September 20, 2017. INTERVENTIONS Standard carewas daily CHX 2% bodywashings and a hand hygiene improvement program. Following a baseline period from 6 to 14 months, each ICUwas assigned in random order to 3 separate 6-month intervention periods with either CHX 2% mouthwash, SOD (mouthpaste with colistin, tobramycin, and nystatin), or SDD (the same mouthpaste and gastrointestinal suspension with the same antibiotics), all applied 4 times daily. MAIN OUTCOMES AND MEASURES The occurrence of ICU-acquired bloodstream infection with MDRGNB (primary outcome) and 28-day mortality (secondary outcome) during each intervention period compared with the baseline period. RESULTS A total of 8665 patients (median age, 64.1 years; 5561 men [64.2%]) were included in the study (2251, 2108, 2224, and 2082 in the baseline, CHX, SOD, and SDD periods, respectively). ICU-acquired bloodstream infection with MDRGNB occurred among 144 patients (154 episodes) in 2.1%, 1.8%, 1.5%, and 1.2% of included patients during the baseline, CHX, SOD, and SDD periods, respectively. Absolute risk reductions were 0.3%(95% CI, -0.6% to 1.1%), 0.6%(95% CI, -0.2% to 1.4%), and 0.8%(95% CI, 0.1% to 1.6%) for CHX, SOD, and SDD, respectively, compared with baseline. Adjusted hazard ratios were 1.13 (95% CI, 0.68-1.88), 0.89 (95% CI, 0.55-1.45), and 0.70 (95% CI, 0.43-1.14) during the CHX, SOD, and SDD periods, respectively, vs baseline. Crude mortality risks on day 28 were 31.9%, 32.9%, 32.4%, and 34.1% during the baseline, CHX, SOD, and SDD periods, respectively. Adjusted odds ratios for 28-day mortality were 1.07 (95% CI, 0.86-1.32), 1.05 (95% CI, 0.85-1.29), and 1.03 (95% CI, 0.80-1.32) for CHX, SOD, and SDD, respectively, vs baseline. CONCLUSIONS AND RELEVANCE Among patients receiving mechanical ventilation in ICUs with moderate to high antibiotic resistance prevalence, use of CHX mouthwash, SOD, or SDD was not associated with reductions in ICU-acquired bloodstream infections caused by MDRGNB compared with standard care.